Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pomona, California 91716


Purpose:

Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.


Criteria:

Inclusion Criteria for Normal Group 1. Subjects 18 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Subjects presenting at the site with normal eyes (eyes without pathology) 4. lOP <=21 mmHg bilaterally 5. BCVA 20/40 or better (each eye) 6. Both eyes must be free of eye disease Exclusion Criteria for Normal Group 1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study 2. Subjects unable to tolerate ophthalmic imaging 3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images 4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses> 20% or false positives> 33%, or false negatives> 33% 5. Visual field defects consistent with glaucomatous optic nerve damage with at least one of the following two findings: 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; 2. Glaucoma hemi-field test "outside normal limits." 6. Presence of any ocular pathology except for cataract 7. Narrow angle 8. History of leukemia, dementia or multiple sclerosis 9. Concomitant use of hydroxychloroquine and chloroquine Inclusion Criteria for Glaucoma Group 1. Subjects 18 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. BCVA 20/40 or better in the study eye 4. Visual field defects consistent with glaucomatous optic nerve damage based on with at least one of the following two findings: 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; 2. Glaucoma hemi-field test "outside normal limits." 5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: 1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage; 2. Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or 3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue Exclusion Criteria for Glaucoma Group 1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study 2. Subjects unable to tolerate ophthalmic imaging 3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images 4. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as fixation losses> 20% or false positives> 33%, or false negatives > 33% in the study eye 5. Presence of any ocular pathology except glaucoma in the study eye 6. History of leukemia, dementia or multiple sclerosis 7. Concomitant use of hydroxychloroquine and chloroquine Inclusion Criteria for Retina Disease Group 1. Subjects 18 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Subjects presenting at the site with retinal disease 4. lOP<= 21 mmHg in the study eye 5. BCVA 20/400 or better in the study eye 6. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others Exclusion Criteria for Retinal Disease Group 1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study 2. Subjects unable to tolerate ophthalmic imaging 3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images 4. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g., cornea pathology) in the study eye 5. Narrow angle in the study eye 6. History of leukemia, dementia or multiple sclerosis 7. Concomitant use of hydroxychloroquine and chloroquine


NCT ID:

NCT02376868


Primary Contact:

Study Director
Charles Reisman, MS
Topcon Corporation


Backup Contact:

N/A


Location Contact:

Pomona, California 91716
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.